The rationale for adopting this strategy was that our recent report found that including the genetic biomarker MYCN to CSV+ CTC positivity boosted the accuracy of predictions of non-relapse from 95% to 100% in neuroblastoma patients who were in remission and receiving maintenance therapy (12). This evidence concerns the gene MYCN and neuroblastoma.